Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.
about
A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancersEpimutational profile of hematologic malignancies as attractive target for new epigenetic therapiesSpliceosomal gene mutations in myelodysplasia: molecular links to clonal abnormalities of hematopoiesisFunctions of TET Proteins in Hematopoietic TransformationApplying a Weight-of-Evidence Approach to Evaluate Relevance of Molecular Landscapes in the Exposure-Disease ParadigmMyelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and managementMolecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?Revisiting the case for genetically engineered mouse models in human myelodysplastic syndrome researchConnections between TET proteins and aberrant DNA modification in cancerThe TET2 interactors and their links to hematological malignanciesCohesin mutations in myeloid malignancies: underlying mechanismsAn extended U2AF(65)-RNA-binding domain recognizes the 3' splice site signalRUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.Genomic Classification and Prognosis in Acute Myeloid Leukemia.Role of TET enzymes in DNA methylation, development, and cancerEmerging concepts of epigenetic dysregulation in hematological malignanciesClonal hematopoiesis in acquired aplastic anemiaMDS prognostic scoring systems – past, present, and futureOral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid LeukemiaLeukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesisMyelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromesMDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significanceClinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasmsManagement of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.Established and emerging targeted therapies in the myelodysplastic syndromes.Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes.[Myelodysplastic syndromes].Molecular Testing in Patients with Suspected Myelodysplastic Syndromes.Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantationHow do messenger RNA splicing alterations drive myelodysplasia?Clinical and genetic predictors of prognosis in myelodysplastic syndromes.Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease.Molecular features of early onset adult myelodysplastic syndromeASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia.Genomic landscape of CD34+ hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers.The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemiaMetallothionein III (MT3) is a putative tumor suppressor gene that is frequently inactivated in pediatric acute myeloid leukemia by promoter hypermethylation.Risk stratification in myelodysplastic syndromes: is there a role for gene expression profiling?Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.
P2860
Q26743743-0AAC719D-CA62-4E9E-BBD8-971DA1181A5DQ26744080-B7EA4824-31DF-4240-BE26-8264277C147DQ26752221-D437338C-83FB-4A51-A517-0DCDB23428C1Q26778323-178C672E-60A2-4D78-A120-BE31B5C3A89BQ26784509-57660CD7-4928-4792-A496-6FC043445312Q26796240-A5730D47-2916-443F-8D6A-DCB706C7822CQ26801573-51A80A5A-3BC6-429C-9CB4-1927DA96F229Q26859843-50DC3468-504D-4052-85ED-27C415E8690DQ26865671-36FD24AC-F5FA-4BF1-89DE-21711195361CQ27002485-DE1DE2C1-125B-4320-AA4A-41821D17A144Q27022740-2BC9688B-CF91-4BE2-8BDB-5C43E4F3F981Q27324522-287FD81E-FDFC-445B-A74D-0AE3FE3A84E2Q27853381-642FE031-A1EF-47CE-A040-B662B21CAFCBQ27853389-48D90A98-6000-41C5-B305-2EF56B7185FEQ28068541-B0222E5F-6BC0-44AE-9C20-CDB0F05BF1F5Q28074522-3BDDA218-FCEC-4FAE-BD54-89A3C6E649DEQ28079733-4120B4E3-185F-4DB0-8EE0-977598675D5AQ28082460-FE72B9C1-FE71-4B88-B0AA-F04550D769F7Q28084813-392A5AC6-6793-488F-A243-BF73474F4B17Q28386212-253E2AC8-FF9A-4501-BFD8-D9A86D37ED28Q28387115-6D034C1E-52BD-4238-931D-713F75678204Q28392451-7E2DEC5D-327F-486C-8074-C7C8BC6A0B97Q28394317-915A8051-387A-44AA-86A0-CE5B73FB6BFAQ29039802-473B0DEA-EFB2-4E18-BBF8-AF29ABCC457CQ30235355-C2F04D6C-049C-4648-AF8D-FCC4D350FE76Q30245476-CC24BE3E-8E63-4680-AF5B-144784EEE336Q30883788-C30B4595-48CB-47D3-B118-57D07D4C64EEQ33420574-096CFAAE-F58C-4C0C-96CB-6327A8107423Q33435980-FC03AD63-64DC-4E8F-9C4E-1741AE604CAEQ33615619-363994C1-6E89-4481-AAE1-4706B6BC56CFQ33640195-FED7F336-9B98-4FE1-9BD4-C51A4A5B5C42Q33695906-FBFF3746-0CE1-4789-B40E-C5A12C00B173Q33709905-54242F5D-7737-44E2-8498-5E8A4D4D75C8Q33746718-A1F9EC18-5660-405D-8FC6-924B53C6ABC9Q33753763-783225CD-A644-4A22-A579-8724782297F0Q33767762-F541CECB-4766-4B05-9351-E0E6A72C7AD5Q33796552-A6E5AFD7-7503-455C-97B6-703A83BEFCF1Q33847875-CBB0337E-A086-4158-9B27-0E289FC3EAFCQ34013786-4E276F93-FA8E-4D44-B1AC-91EF94AC9208Q34047259-B07F3BB8-A080-4150-A020-748AD47BDA85
P2860
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.
@en
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.
@nl
type
label
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.
@en
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.
@nl
prefLabel
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.
@en
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.
@nl
P2093
P2860
P50
P356
P1433
P1476
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.
@en
P2093
A Kohlmann
H Aburatani
H P Koeffler
P2860
P2888
P304
P356
10.1038/LEU.2013.336
P577
2013-11-13T00:00:00Z